Teva Pharmaceutical Industries Ltd

Contributing Author

Recent Articles by Teva Pharmaceutical Industries Ltd

May-30	New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 TEVA GlobeNewswire
May-30	Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date TEVA GlobeNewswire
May-29	Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day TEVA GlobeNewswire
May-27	Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA TEVA GlobeNewswire
May-27	Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June TEVA GlobeNewswire
May-27	Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma TEVA GlobeNewswire
May-22	Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes TEVA GlobeNewswire
May-20	Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt TEVA GlobeNewswire
May-20	Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy TEVA GlobeNewswire
May-19	Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 TEVA GlobeNewswire
May-19	Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes TEVA GlobeNewswire
May-15	Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy TEVA GlobeNewswire
May-12	Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy TEVA GlobeNewswire
May-07	Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City TEVA GlobeNewswire
May-07	Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved TEVA GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) TEVA GlobeNewswire